

Impact Statement

1. MTIP's sustainable investment objective

Our funds have sustainable investment as the objective, meaning investments in a business that contributes to a social objective, in particular investments that contributes to tackling inequality in access to quality health-care.

Our investments contribute to a future vision that economically or socially disadvantaged communities can also get the preventive care, diagnosis, treatments, and monitoring that they need, which fosters social cohesion, social integration, and better labor relations.

We screen opportunities for sustainable investments as explained above, while ensuring they fulfil the "Do No Significant Harm" principal. We also ensure that investee companies follow good governance practices during our due diligence.

As of December 2020, more than 50% of our portfolio companies delivered products and services that contribute to tackling inequality in access to quality healthcare, such as devices for telehealth, digital nutrition-related therapy, and digital mental health. Despite lockdowns, most of our portfolio was able to continue and, in many cases, expand operations in the year 2020, rapidly increasing the number of patients served and lives saved. Going forward we intend to continue allocating more than 50% of MTIP Fund II to companies that contribute to the above-mentioned social objective.

2. MTIP considers principal adverse impacts of its investment decisions on sustainability factors

We have created a list of ESG-related KPIs to track the ESG performance of our investee companies, and to make sure we achieve our sustainable investment objective. Indicators applicable to our investee companies are related to social and employee matters, human rights, anti-corruption, and anti-bribery.

Given our focus on HealthTech companies, which excludes biotech and pharma companies, the adverse sustainability indicators related greenhouse gas emissions, biodiversity, water and waste are not applicable for our investee companies.

ESG due diligence forms a standard part of our rigorous due diligence process prior to an investment into a company.

- + For each potential investment opportunity, we analyze the unmet medical need that the company tries to address and closely examine how their products or services would serve this unmet need. More than 50% of our portfolio companies create value by addressing unmet medical needs, thereby improving access to quality healthcare.
- + Prior to the initial investment in a company, we look at all applicable ESG risks. We only invest in companies where these risks are either insignificant or manageable. Following the invest, we engage with the management teams, where necessary, to further improve their ESG performance and reporting, which helps us consistently meet our sustainable investment objective.

